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Abstract 
Background 
Women with twin pregnancy are at high risk for spontaneous preterm delivery. Progesterone 
appears to be effective in reducing preterm birth in selected high risk singleton pregnancies, albeit 
with no significant reduction in perinatal mortality and limited evidence of neonatal benefit (1). 
Methods. 
Five hundred women with twin pregnancy were recruited from UK NHS clinics specialising in 
the management of twin pregnancy. Women were randomised either to daily vaginal 
progesterone 90mg (Crinone®) or to placebo, given double blind for ten weeks from 24 weeks 
gestation. The primary outcome was delivery (or intrauterine death) prior to 34 weeks gestation 
(ISRCTN 35782581). Additionally we performed a meta-analysis of our own and other published 
(and unpublished) data to determine the efficacy of progesterone in preventing early (< 34 weeks 
gestation) preterm birth or intrauterine death in women with twin pregnancy. 
Findings 
The combined proportion of intrauterine death or delivery prior to 34 weeks of pregnancy was 
24.7% (61/247) in the progesterone and 19.4% (48/247) in the placebo group, odds ratio [95% 
CI] of 1.36 [0.89 to 2.09]. Meta-analysis confirmed that progesterone does not prevent early 
preterm birth (OR of delivery before 34 weeks of 1.16 [95% CI 0.89 to 1.51]) in women with 
twin pregnancy. 
Interpretation 
Progesterone, administered vaginally, fails to prevent preterm birth in women with twin 
pregnancy. Our data complement those of Rouse (2) who showed that 17 hydroxyprogesterone 
caproate, administered intramuscularly, failed to prevent preterm birth in twin pregnancy. 
Different pathophysiological mechanisms may account for the apparent difference in efficacy of 
progesterone in high risk singleton and twin pregnancy. Progestogens should not be used to 
prevent preterm birth in twin pregnancy. 
 
Introduction 
 
Multiple births (of which almost all are twins) have been increasing as a percentage of maternities 
since 1976. In the UK, multiple pregnancies accounted for 1.6% of all births in 2007 (3, 4), with 
over 98% of these multiple births being twin births (4) Stillbirth and neonatal mortality rates for 
multiples are 14.9 and 19.8 per 1000 live births respectively: rates 3 – 8 times higher than for 
singleton pregnancies (5). The economic costs of health care provision in the first five years of 
life are twice as high per child following twin compared with singleton birth (6). Prematurity 
continues to be the major cause neonatal death amongst multiple births, with preterm labour 
potentially the most treatable cause of prematurity amongst multiples (5). In the longer term, the 
morbidity amongst both singleton and multiple survivors of preterm birth is well documented, 
leading to poorer health and reduced achievement both in school and in adulthood. Such 
morbidity is associated with major financial costs to the health service, as well as personal 
suffering to the individuals and their families. 
 
No effective interventions have been documented to prevent preterm delivery in twin pregnancy. 
In contrast, the efficacy of progesterone to prevent preterm delivery in high risk singleton 
pregnancy has been demonstrated in three large randomised trials and supported by subsequent 
meta-analyses (1, 7-9). The likelihood of preterm birth in women with singleton pregnancy 
identified at risk of preterm delivery either because of a previous preterm delivery (7, 8) or a 
short cervix (9) is reduced by antenatal progesterone. Importantly, there is little evidence that this 
reduction in preterm birth rate is accompanied by neonatal benefit since there is no reduction in 
perinatal mortality, and neonatal sepsis is the only secondary neonatal outcome whose risk is 
reduced in babies of women with singleton pregnancy treated with antenatal progesterone (1). 
Notwithstanding, the effect of progesterone in reducing preterm birth in singleton pregnancies at 
high risk means that there is great interest in whether progesterone could reduce the risk of 
preterm delivery in twin pregnancy. The STOPPIT study, reported here, was designed to test the 
hypothesis that the occurrence of delivery (or intrauterine death) before 34 weeks and 0 days 
gestation would be lower in women with twin pregnancy randomized to progesterone gel 90mg 
(daily from 24 – 34 weeks gestation) compared to matching placebo. 
 
Methods 
Randomised clinical trial 
 
Participants. 
Women were recruited from specialised antenatal clinics caring for women with multiple 
pregnancy at the following UK NHS hospitals: The Royal Infirmary, Edinburgh; Princess Royal 
Maternity, Glasgow; Royal Victoria Infirmary, Newcastle; The Queen Mother’s Hospital, 
Glasgow; Ninewells Hospital, Dundee; Aberdeen Maternity Hospital; Forth Park Hospital, 
Kirkcaldy; University Hospital of Coventry and Warwickshire; The City Hospital, Nottingham 
and Birmingham Women’s Hospital. All women with a twin pregnancy, with gestation and 
chorionicity established by scan prior to 20 weeks gestation, and attending during the recruitment 
period were eligible for recruitment. Women were not eligible if their pregnancy was complicated 
by a recognized structural or chromosomal fetal abnormality at the time of recruitment,  
ontraindications to progesterone, planned cervical suture, planned elective delivery before 34 
weeks gestation or intervention for twin to twin transfusion before 22 weeks gestation. 
 
Interventions 
Participants were randomised either to daily progesterone (90mg) (Crinone®) or placebo gel 
administered vaginally by the participant and starting at 24 weeks + 0 days gestation. Drugs were 
supplied in a sealed opaque covering. Each cover contained a single use, one piece, white 
polyethylene applicator with a twist-off top, designed for intravaginal selfinsertion. Each 
applicator contained 1.45 g of gel and delivered 1.125g of gel, containing either 8% progesterone 
or excipients (glycerin, light liquid paraffin, hydrogenated palm oil glyceride, carbopol 974P, 
sorbic acid, polycarbophil, sodium hydroxide and purified water). 
 
Objectives 
The aim was to determine whether vaginal progesterone gel, 90mg daily from 24 – 34 weeks 
gestation, reduces the rate of preterm delivery (or intrauterine death) before 34 weeks in women 
with twin pregnancy. Specifically, we hypothesised that the proportion of women delivering (or 
with intrauterine death) before 34 weeks and 0 days gestation following progesterone would be 
less than with placebo. 
 
Outcomes 
The primary outcome was delivery (or intrauterine death) before 34+0 weeks gestation. We used 
delivery of the first twin to define the time of delivery. If one twin died in utero before 34 weeks 
and the other was born alive after 34 weeks, intrauterine fetal death was defined as occurring 
before 34 weeks. The gestational age was calculated from the agreed early (before 20 weeks) 
ultrasound scan. The maternal secondary outcomes were gestation at delivery, mode of delivery 
(spontaneous vaginal delivery [SVD], vaginal breech, forceps/ventouse, or caesarean section), 
duration of each stage of labour, and safety outcomes such as prolongation of hospitalisation. 
Neonatal secondary outcomes include neonatal unit admission and duration of neonatal unit care. 
We also ascertained maternal satisfaction by questionnaire. Women were followed up from 
randomisation until birth. Outcomes were recorded from the hospital notes, and entered into a 
web-based data capture system by a trained clinician, usually a study midwife. 
 
Sample size 
The proportion of deliveries before 34 weeks gestation in twin pregnancy is approximately 20% 
(personal communication, Dr J Chalmers, Information Services Division, NHS Scotland). Our 
study size of 250 women per group gave 85% power at 5% significance level to show a reduction 
in the rate of preterm delivery (or intrauterine death) prior to 34 weeks gestation from 20% to 
10% in the active treatment group and was based on a conservative estimate of likely effect size 
derived from previous studies (7, 8). 
 
Randomisation. 
We aimed to recruit and randomise women at 22 weeks gestation. Where possible, the project 
was discussed with women at booking, and again at 22 weeks gestation. All women had at least 
one week to decide whether to participate. Participants gave written informed consent and the 
study was granted approval by the West Glasgow Ethics Committee 1 (reference 04/S0703/13). A 
randomisation schedule using permuted blocks of randomly mixed sizes was used to make up 
treatment packs (either active or placebo) for each patient, which were held in individual hospital 
pharmacies until use. On recruitment, the local researcher (usually a midwife) telephoned the 
Interactive Voice Response randomisation application at the UK CRN registered trials unit (The 
Centre for Healthcare Randomised Trials [CHaRT], in the Health Services Research Unit, 
University of Aberdeen), to be given a participant number which corresponded to a specific 
treatment pack. A minimization algorithm incorporating hospital and chorionicity was used to 
assign participants to the randomised treatment group.  
 
Masking 
All study personnel and participants were blind to treatment assignment for the duration of the 
study. Only the study statistician and the independent Data Monitoring Committee had access to 
unblinded data, but none had any contact with study participants. 
 
Statistical methods 
Analysis was according to the intention-to-treat principle and followed a pre-specified Statistical 
Analysis Plan. For the primary outcome the odds ratio of the treatment effect, adjusting for the 
minimisation covariate (chorionicity), was estimated with a 95% confidence interval, and 
associated likelihood ratio P-value, using logistic regression. A predefined subgroup analysis of 
the primary outcome by monochorionicity (Yes/No) was undertaken. Continuous maternal 
secondary outcomes were analysed using normal linear regression models, adjusting for 
chorionicity. Treatments effects, 95% confidence intervals and P-values were calculated as 
described in the statistical analysis plan. Binary categorical secondary outcomes were analysed 
using logistic regression as per the primary outcome. For data with multiple categories (e.g. mode 
of delivery) the two randomised groups were compared using a proportional odds model. Fetal 
outcomes allowed for the clustering within twins. Analyses were as for the maternal outcomes 
except with the addition of mother as a random effect in the linear and logistic regression models. 
No missing data were imputed. No adjustment was been made for any multiple comparisons. An 
independent Data Monitoring Committee met regularly throughout the study. No formal interim 
analyses were undertaken, and so no adjustment is required for this. All statistical analyses were 
undertaken in SPSS for Windows, Rel. 17.0.0 (2008, Chicago, SPSS Inc.) and Stata, StataCorp, 
2009, Statistical Software: Release 10.1. College Station, TX: Stata Corporation. 
 
Trial registration. The trial was registered on EUDRAct (2004-000780-10) and ISRCTN 
(35782581). 
 
 Meta-analysis 
We performed an electronic search of the published medical literature (PubMed and Cochrane 
Controlled Trials Register) for studies where women with twin pregnancy were randomly 
allocated to treatment with a progestogen (including progesterone, 17 hydroxyprogesterone 
caproate) or placebo in the second or third trimester with the intention of preventing preterm 
birth. We used the search terms “preterm birth” AND [“progesterone” OR “17 
hydroxyprogesterone caproate” OR “progestogen”] AND [“pregnancy multiple” OR “pregnancy 
twin”] AND “randomised controlled trial” AND “human”. All published randomised controlled 
trials in humans in which progestogens were administered to women with twin pregnancy for the 
prevention of preterm birth were considered. Those in which progestogens were administered to 
women with symptoms of preterm labour, or where data were available in abstract form only 
were excluded. Two reviewers (JEN and JN) reviewed identified papers for relevance and quality 
and abstracted the data. Published studies were assessed for quality according to Jadad’s quality 
assessment scale (10). 
 
Our pre-specified primary outcomes were the incidence of delivery (or intrauterine fetal death) 
before 34 weeks gestation. Where data on our primary outcome of interest was not available in 
the published report, we successfully contacted the relevant chief investigator to get the required 
information. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated for the 
primary outcome.  
 
Role of the funding source. 
The funder (Chief Scientist’s Office, Scottish Government) and the supplier of active and 
placebo drugs (Serono) had no role in study design; in the collection, analysis, and interpretation 
of data, in the writing of the report or and in the decision to submit the paper for publication. The 
joint study “sponsor” in terms of the EU Clinical Directive was the University of Glasgow / 
Greater Glasgow Health Board. The sponsor had no role in analysis of data. JEN is the 
corresponding author and confirms that she had full access to all the data in the study and had 
final responsibility for the decision to submit for publication. 
 
Results 
 
The flow of participants through the STOPPIT study is shown in Figure 1. Participants attended 
clinic visits at the time of randomisation (baseline), at intervals during pregnancy and were 
admitted to the study hospital for delivery and postnatal care. Participants were recruited from 
December 2004 to April 2008. The baseline demographics and clinical characteristics of the 
participants are shown in Table 1. Three patients in each of the progesterone and the placebo 
group were lost to follow up (due to withdrawal of consent or not traceable after moving out of 
study area); thus data from 494 patients were available for the intention-to-treat analysis of the 
primary outcome. No patients were considered protocol violators, and none were unblinded prior 
to ascertainment of all outcomes. Consequently 494 patients remained for the per-protocol 
analyses.  
 
The proportions of women delivering or with an intrauterine death before 34 weeks in the 
progesterone and the placebo group were 61/247 [24.7%] and 48/247 [19.4%] respectively (Table 
2). The odds ratio (OR) (95% confidence interval [CI]) of preterm delivery (or intrauterine death) 
before 34 weeks gestation in association with progesterone was 1.36 (95% CI 0.89 to 2.09), 
P=0.16. Thus, in contrast to our original hypothesis, progesterone did not reduce the incidence of 
preterm delivery (or intrauterine death) before 34 weeks gestation. Subgroup analysis of the 
primary outcome by chorionicity showed a significant increase in the rate of preterm delivery (or 
intrauterine death) before 34 weeks in association with progesterone amongst women with 
dichorionic pregnancies. However, the P-value for the formal test of interaction between the 
mono- and dichorionic groups did not reach statistical significance (P=0.056), implying that the 
response to treatment in the monochorionic and dichorionic group was not formally significantly 
different. Thus the finding of increased rates of adverse outcomes in the dichorionic group should 
be interpreted with suitable caution. 
 
Secondary maternal outcomes are shown in Table 3, neonatal outcomes in Table 4, safety issues 
in Table 5, side effects in Table 6, and maternal satisfaction in Table 7. The only apparent 
differences between the groups were reduced odds of caesarean [OR 0.53 (95% CI 0.34 to 0.84), 
P=0.006], operative vaginal delivery [OR 0.42 (95% CI 0.21 to 0.83), P=0.013], and nausea [OR 
0.43 (0.20 to 0.94), P=0.035] in the progesterone group. There were no differences in the rate of 
adverse events between the two groups, despite a trend towards an increased occurrence of 
intrauterine death, neonatal death and hospitalisation/prolongation of hospitalisation amongst the 
progesterone group. Regarding compliance, 136 women in the progesterone group and 151 
women in the placebo group returned diaries indicating that they had taken 56/70 (80%) or 
greater proportion of their medication. The remainder either failed to return their diary or stopped 
early because of preterm delivery or because they were told to stop, or were incompletely 
compliant with treatment. 
 
Meta-analysis 
Electronic searching of the literature generated 198 results relevant for meta-analysis. Review of 
the abstracts indicated that only two fulfilled the inclusion criteria. Relevant data could be 
abstracted from one of these papers (2). Given the discrepancy between the published primary 
outcome (spontaneous preterm delivery before 34 weeks gestation) and the outcome we planned 
for the meta-analysis (intrauterine death or any preterm delivery before 34 weeks gestation) we 
contacted the senior author of the other paper (9) who generously supplied the relevant data. A 
further paper (11) did not appear on electronic searching, but was brought to the attention of the 
authors and considered for inclusion. Further reading of this paper showed that the primary 
outcome (spontaneous preterm delivery prior to 37 completed weeks of gestation) was again 
different from the one we planned in the meta-analysis, and given the long time interval since 
publication of this paper in 1980, it was not considered that contacting the author for further 
information would be helpful. Both trials included in the meta-analysis were rated as of highest 
quality according to the Jadad score (10). The pooled OR (95% CI) of the effect of progesterone 
in preterm delivery (or intrauterine death) before 34 weeks gestation was 1.16 (0.89 to 1.51) 
(Table 8 and Figure 9). 
 
Discussion 
 
We have shown that progesterone did not reduce the composite outcome of risk of delivery or 
intrauterine death prior to 34 weeks of pregnancy in women with twin pregnancy. Our results are 
in agreement with the other large published trial in twin pregnancy which used 17 
hydroxyprogesterone caproate, 250mg given intramuscularly from 16 – 20 to 35 weeks, and with 
the most recent meta-analysis on this issue (1). The relative risk of preterm birth (or intrauterine 
death) prior to 34 weeks in the 655 women available for analysis was 1.1 (0.9 to 1.3) in the active 
compared with the placebo group (2).. A new meta-analysis of the STOPPIT data reported here, 
together with data from the other two relevant published studies also supports the findings of this 
trial, that progesterone does not reduce intrauterine death or preterm delivery (before 34 weeks 
gestation), with an odds ratio (95% CI) of 1.16 (0.89 to 1.51).  
 
Our study has the following strengths. It was a double-blind placebo-controlled trial with central 
randomisation, a prespecified sample size which was achieved, a prespecified primary endpoint 
and analysis plan which was followed and a high rate of follow-up. Loss to follow up for the 
primary outcome was only 6/500 [1.2%]. We believe that the generalisability of the trial is good. 
Our exclusion criteria were few, and thus 84% (1249/1483) of women with twin pregnancy were 
eligible for the study. We are confident therefore that we have ruled out a clinically important 
reduction in delivery before 34 weeks in this group of patients.  
 
Potential weakness of our study are that the uptake of the study amongst eligible participants was 
less than we initially anticipated with only 40% (500 / 1249) of eligible women agreeing to 
participate, and that the study was largely conducted in tertiary referral centres. These issues may 
have affected the external validity of our trial although this is unlikely. The overall rate of 
preterm delivery or intrauterine death (before 34 weeks) was 22% (109 / 494), which is similar to 
another (singleton) study where progesterone was shown to be effective (7).. The dose of vaginal 
progesterone was similar to the dose used in one singleton study that demonstrated efficacy (7), 
although less than that in another (9). The dose we used is at the lower end of demonstrated 
effective doses, but meta-analyses have not demonstrated a dose response effect (12). We believe 
therefore that it is unlikely that the dose of progesterone we used was too small.  
 
Our unexpected observation of overall lower rates of both caesarean section and operative 
vaginal delivery in the progesterone group should be interpreted with caution. There was no 
effect on any other labour parameters, and no significant effect when prelabour and postlabour 
caesarean sections were considered separately. The effect on caesarean was not seen in other 
large studies using progesterone twin pregnancy (relative risk [95% CI] of 1.0 [0.9 to 1.1]) (2) or 
singleton pregnancy (relative risk [95% CI] 0.94 [0.68 to 1.30]) (8). It is unlikely that 
progesterone reduced caesarean section by improving fetal wellbeing, in view of the trend 
towards increased perinatal mortality in STOPPIT (14 deaths versus 10 deaths). Nor is it likely 
that progesterone improved uterine contractility during labour given that it is known to have a 
relaxant, rather than a stimulatory effect on the uterus (13). Given that the reduction in caesarean 
section is one of a number of secondary outcomes in our study, the lack of biological plausibility 
and lack of confirmation from other studies, we believe that this is most likely to be a chance 
finding.  
 
The clinical implication of our study is that progestogens should not be given to women 
with twin pregnancy for prevention of preterm delivery. Although to our knowledge six further 
clinical trials of the effect of 17 hydroxyprogesterone caproate / progesterone in the prevention of 
preterm delivery in twin pregnancy are ongoing: two large trials (NCT 00329914 [with a planned 
sample size of 750]) and ISRCTN40512715 [with a planned sample size of 660]) and four 
smaller trials (NCT 00343265, NCT 00480402, NCT 00141908 and NCT 00163020, with a 
combined planned sample size of 957), unless their combined effect size is large with an odds 
ratio of 0.65 or less, they will not change the overall conclusion of this and the previous(2) study 
that progesterone is ineffective. 
 
Our results contrast with the randomised trials and meta-analyses of high risk singleton 
pregnancies where progesterone appears to be effective in reducing preterm birth, although this 
reduction in preterm birth will only be clinically useful if accompanied by longer term improved 
offspring health. At present, there is no evidence that this is the case. We and others are 
specifically addressing this issue in singletons in a randomized trial of progesterone with infant 
function at 2 – 3 years of age as our primary outcome (OPPTIMUM – www.opptimum.org.uk. 
ISRCTN 14568373). The biological mechanism by which preterm delivery occurs may be 
different in twin and singleton pregnancy, and this merits further study. Perhaps stretch plays a 
more significant role in preterm labour in twin pregnancy and infection / inflammation a role in 
singletons. We did not recruit women with higher multiple pregnancy (eg triplets), but a recent 
publication again failed to demonstrate any effect of progesterone in preventing preterm birth in 
triplet pregnancy (14). 
 
We conclude that progesterone is ineffective in reducing the high risk of preterm birth and 
intrauterine death in twins and the results of our study show possible (albeit non significant) 
evidence of harm. Progestogens should not routinely be given for prevention of preterm delivery 
in uncomplicated twin pregnancy. 
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Table 1: Baseline characteristics 
 
Characteristic Level Progesterone 
N = 250 
Placebo 
N = 250 
Demographics and Lifestyle 
Age Mean(SD) 33 (5) 33 (6) 
Min-Max 18, 44  19, 50 
Current Smoking Yes n(%) 44 (17.6) 31 (12.4) 
Current Alcohol Yes n(%) 179 (71.6) 177 (70.8) 
Obstetric History 
Parity >0 n (%) 119 (47.6) 122 (48.8) 
Miscarriage >0 n (%) 3 (1) 1 (0) 
Medical conditions 
Hypertension Yes n (%) 3 (1) 1 (0) 
Insulin dependent diabetes Yes n (%) 1 (0) 1 (0) 
Respiratory disease Yes n (%) 8 (3) 17 (7) 
Cardiac disease Yes n (%) 2 (1) 1 (0) 
Neurological disease Yes n (%) 0 (0) 1 (0) 
Skin condition Yes n (%) 4 (2) 8 (3) 
Thrombophilia Yes n (%) 2 (1) 2 (1) 
Current Pregnancy 
Fetal anomaly scan: Twin 1 Normal n (%) 242 (97) 243 (97) 
 Defined 
abnormality n 
(%) 
3 (1) 1 (0) 
 Uncertain 
abnormality n 
(%) 
0 (0) 0 (0) 
 Not done n (%) 5 (2) 6 (2) 
Fetal anomaly scan : Twin 2 Normal n (%) 242 (97) 242 (97) 
 Defined 
abnormality n 
(%) 
3 (1) 2 (1) 
 Uncertain 
abnormality n 
(%) 
0 (0) 0 (0) 
 Not done n (%) 0 (0) 0 (0) 
Amniocentesis : Twin 1 Abnormal 0 (0) 0 (0) 
Amniocentesis : Twin 2 Abnormal 0 (0) 0 (0) 
CVS Performed 1 (0) 0 (0) 
 
CVS – chorionic villus sampling 
 
Table 2: Primary Outcome – overall and by subgroup of chorionicity 
 
Outcome Progesterone Placebo Progesterone: 
placebo 
Odds Ratio 
(95% CI) 
p-value 
 N Event (%) N Event (%)   
All pregnancies 
Proportion of 
women 
delivering (or 
with intrauterine 
death) before 34 
weeks n (%) 
247 61 (24.7) 247 48 (19.4) 1.36 
(0.89, 2.09) 
0.16* 
Monochorionic pregnancies 
Proportion of 
women 
delivering (or 
with intrauterine 
death) before 34 
46 10 (21.7) 45 14 (31.1) 0.62 
(0.24, 1.58) 
 
Dichorionic pregnancies 
Proportion of 
women 
delivering (or 
with intrauterine 
death) before 34 
weeks n (%) 
201 51 (24.5) 202 34 (16.8) 1.73 
(1.06, 2.83) 
 
* refers to p value for proportion in progesterone versus placebo group (from a logistic regression 
model adjusting for chorionicity) 
 
P-value for Test of Interaction between monochorionic and dichorionic pregnancies: 
p=0.056 
 
Table 3: Secondary Outcomes: gestational age at birth, duration of labour, and 
method of delivery 
 
Characteristic Progesterone Placebo Mean 
difference 
(95% CI) 
P-value 
 N Mean (SD) N Mean (SD)   
Gestational 
age birth 
(weeks) 
247 35.4 (3.5) 247 35.7 (3) -0.3 (-0.9, 
0.3) 
0.31 
Duration 
Labour Stage 
1 mins* 
82 327 (284) 63 360 (380) -33 (-142, 
75) 
0.55 
Duration 
Labour Stage 
2 mins* 
82 102 (94) 63 116 (91) -14 (-45, 
17) 
0.36 
Duration 
Labour Stage 
3 mins* 
82 19 (28) 63 16 (29) 3 (-6, 12) 0.53 
Duration 
Labour 
Overall mins* 
82 447 (327) 63 496 (418) -48 (-171, 
74) 
0.44 
       
Method of 
Delivery 
(hierarchical) 
N Event(%) N Event(%) Odds ratio 
(95% CI) 
 
Not recorded 250 14 (5.6%) 250 21 (8.4%)   
LSCS 250 148 
(59.2%) 
250 161 
(64.4%) 
0.53 
(0.34, 0.84) 
0.006 
Forceps or 
ventouse 
250 22 (8.8%) 250 30 (12.0%) 0.42 
(0.21, 0.83) 
0.013 
SVD or 
vaginal breech 
250 66 (26.4%) 250 38 (15.2%) (referent) (referent) 
 
LSCS - lower segment caesearean section, SVD – spontaneous vertex delivery, 
*vaginal deliveries only 
 
Table 4 : Neonatal Complications: admission to neonatal unit, and duration of neonatal unit 
stay. These data refer to all twins, both the first and second with the 95% confidence interval and P-
values are adjusted for clustering amongst the twin set. 
 
Characteristic Progesterone  Placebo  Progesterone 
vs. Placebo 
(95% CI) 
Pvalue 
 N Event (%) N Event 
(%) 
Odds Ratio  
Neonatal unit 
Admission 
494 167 
(33.4%) 
494 158 
(31.6%) 
1.08 
(0.76, 1.54) 
0.647 
 N Mean 
(SD) 
N Mean 
(SD) 
  
Duration of 494 7.5 (19.9) 495 8.7 (23.1) 1.5 0.38 
neonatal unit 
care – all 
babies 
(days) 
(-1.9, 5.0) 
Duration of 
neonatal unit 
care – just 
babies 
admitted 
to neonatal 
unit 
(days) 
167 26.9 (33.5) 158 23.6 
(29.5) 
3.3 
(-5.3, 11.9) 
0.45 
 
 
Table 5 – Safety Issues. P-value from Fisher’s Exact test on subjects. 
 
Type Progesterone 
Subjects 
(Events) 
Placebo 
Subjects 
(Events) 
P-value 
from 
exact 
test 
Mother died 0 0 1.00 
Intrauterine death 6 4 0.52 
Neonatal death 8 6 0.59 
Involved or prolonged 
inpatient maternal 
hospitalisation 
87 (103) 72 (87) 0.16 
Involved 
persistent/significant 
maternal 
disability/incapacity 
1 0 0.32 
Life threatening 1 2 0.56 
Chorioamnionitis or 
intrauterine infection 
0 0 1.00 
Congenital anomaly / 
birth defect 
0 0 1.00 
 
 
Table 6 – Tertiary Outcome, Maternal Symptoms. Data shown are any reported 
symptom at either of the 6 or the 10 week visit, without adjustment for the baseline 
measure. 
 
Characteristic N Event % N Event % Odds Ratio 
Progesterone 
versus 
Placebo 
(95% CI) 
P-value 
 Progesterone Placebo    
Bloating 187 6 3 191 5 3 1.23 (0.37, 
4.11) 
0.73 
Fluid retention 187 20 11 191 22 12 0.92 (0.48, 
1.75) 
0.80 
Breast 
tenderness 
187 14 7 191 12 6 1.20 (0.54, 
2.68) 
0.64 
Excessive 187 2 1 191 2 1 1.02 (0.14, 0.98 
weight gain 7.33) 
Nausea 187 10 5 191 22 12 0.43 (0.20, 
0.94) 
0.035 
Headache 187 8 4 191 17 9 0.45 (0.19, 
1.09) 
0.077 
Dizziness 187 8 4 191 9 5 0.90 (0.34, 
2.40) 
0.84 
Difficulty 
sleeping 
187 31 17 191 40 21 0.75 (0.45, 
1.26) 
0.28 
Drowsiness 187 8 4 191 4 2 2.09 (0.62, 
7.06) 
0.24 
Depression 187 6 3 191 5 3 1.23 (0.37, 
4.11) 
0.73 
Itching 187 19 10 191 21 11 0.92 (0.48, 
1.77) 
0.79 
Rash 187 7 4 191 4 2 1.82 (0.52, 
6.32) 
0.35 
Acne 187 4 2 191 2 1 2.07 (0.37, 
11.42) 
0.41 
Excessive hair 
growth 
187 3 2 191 4 2 0.76 (0.17, 
3.45) 
0.73 
Hair loss 187 1 1 191 1 1 1.02 (0.06, 
16.45) 
0.99 
Jaundice 
(yellow skin) 
187  0 191  0   
Allergic 
reactions 
187 1 1 191 1 1 1.02 (0.06, 
16.45) 
0.99 
Vaginal 
irritation 
187 20 11 191 15 8 1.45 (0.70, 
2.83) 
0.34 
Vaginal 
itching 
187 19 10 191 18 9 1.09 (0.55, 
2.14) 
0.81 
Vaginal 
discharge 
187 59 32 191 46 24 1.45 (0.92, 
2.29) 
0.11 
Vaginal 
discomfort 
187 24 13 191 17 9 1.51 (0.78, 
2.91) 
0.22 
Joint pain 187 11 6 191 13 7 0.85 (0.37, 
1.96) 
0.71 
Pubic pain 187 6 3 191 5 3 1.23 (0.37, 
4.11) 
0.73 
 
 
Table 7 – Tertiary outcome: Maternal Satisfaction. Data shown are Mean(SD) 
over 2 visits (6 and 10 weeks), adjusted for the baseline measure. 
 
Characteristic  Progesterone 
N =153 to 158 
Placebo 
N = 159 
to 169 
Odds Ratio 
Progesterone 
- Placebo 
(95% CI) 
P-value 
How satisfied 
were you 
with your 
study 
treatment 
overall? 
1=Very 
satisfied 
10=complet 
ely 
dissatisfied 
2.8 (2.1) 2.8 (1.9) 0.0(,0.5, 0.4) 0.89 
Do you think 
your study 
treatment 
worked? 
1=Yes, 
worked 
perfectly 
10=no, did 
not work at 
all 
3.8 (2.3) 3.9 (2.5) -0.1(,0.6, 0.4) 0.73 
How easy was 
your 
treatment to 
use overall? 
1=very easy 
10=very 
difficult 
2.6 (1.9) 2.5 (1.7) 0.2 (-0.2, 0.6) 0.38 
How easy was 
your 
treatment to 
insert? 
1=very easy 
10=very 
difficult 
2.6 (1.9) 2.4 (1.7) 0.2 (-0.2 , 0.6) 0.30 
How easy was 
your 
treatment to 
remember to 
use? 
1=very easy 
10=very 
difficult 
2.6 (1.7) 2.9 (1.7) -0.2 (-0.6, 0.2) 0.26 
How pleasant 
was your 
treatment to 
use? 
1=very 
pleasant 
10=very 
unpleasant 
4.8 (2.0) 4.9 (1.8) -0.1 (-0.5, 0.3) 0.60 
How messy 
was your 
treatment to 
use? 
1=very 
messy 
10=not at 
all messy 
5.5 (2.5) 6.1 (2.4) -0.6 (-1.1, 0.1) 0.026 
How 
uncomfortable 
was 
your treatment 
to use? 
1=very 
uncomfortab 
le 10=very 
comfortable 
6.4 (2.5) 6.5 (2.3) -.01 (-0.6 , 
0.4) 
0.65 
Were there 
many side 
effects of the 
study 
treatment 
overall? 
1=a lot of 
side effects 
10=no side 
effects 
8.2 (2.3) 8.4 (1.9) -0.2 (-0.7, 0.2) 0.32 
An alternative 
would be 
an 
intramuscular 
injection 
once per week. 
If this 
injection were 
only a bit 
uncomfortable, 
which 
would you 
prefer? 
1=daily 
vaginal gel 
10=weekly 
injection 
4.3 (3.6) 4.2 (3.6) 0.2 (-0.6, 0.9) 0.70 
If this 
injection was 
quite 
1=daily 
vaginal gel 
10=weekly 
3.3 (3.0) 3.1 (2.9) 0.2 (-0.4, 0.9) 0.50 
uncomfortable, 
which 
would you 
prefer? 
injection 
Overall, how 
satisfied were 
you with 
participating in 
the STOPPIT 
study? 
1=Very 
satisfied 
10=complet 
ely 
dissatisfied 
2.5 (2.2) 2.1 (1.6) 0.4 (-0.1, 0.8) 0.093 
 
 
Table 8 – Meta-analysis of the effect of progesterone in preventing preterm 
delivery before 34 weeks gestation 
 
Author Progesterone Placebo 
 N Events N Events 
Fonseca 11 4 13 7 
Rouse 325 93 330 89 
Norman 247 61 247 48 
     
 
 Odds ratio (95% CI) % Weight 
Fonseca 0.49 (0.10, 2.53) 3.95 
Rouse 1.09 (0.77, 1.53) 61.05 
Norman 1.36 (0.89, 2.09) 35.00 
   
M-H pooled OR 1.16 (0.89, 1.51) 100 
 
Figure1: Flow of participants through the STOPPIT study 
1483 assessed for eligibility 
250 allocated to placebo 
250 received allocated intervention 
0 didn’t receive allocated intervention 
983 excluded as follows 
Not meeting eligibility 234 
Declined to participate 749 
Other reasons 0 
247 analysed 
3 excluded from analysis (no 
outcome data available) 
247 analysed 
3 excluded from analysis (no 
outcome data available) 
3 lost to follow up 
(delivered outwith booking hospital 
and no information available) 
500 randomised 
3 lost to follow up 
(delivered outwith booking hospital 
and no information available) 
250 allocated to progesterone 
250 received allocated intervention 
0 didn’t receive allocated intervention 
